Tafinlar 10 mg/1
dabrafenib · TABLET, FOR SUSPENSION · Novartis Pharmaceuticals Corporation
Tafinlar is a tablet, for suspension containing dabrafenib at 10 mg/1, taken oral. Manufactured by Novartis Pharmaceuticals Corporation.
Key Facts
- Brand Name
- Tafinlar
- Generic Name
- dabrafenib
- NDC Code (Product)
0078-1154- Manufacturer
- Novartis Pharmaceuticals Corporation
- Strength
- 10 mg/1
- Dosage Form
- TABLET, FOR SUSPENSION
- Route
- ORAL
- Marketing Status
- Application #
- NDA217514
- Marketing Start
- 03/16/2023
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is Tafinlar used for?
Tafinlar contains dabrafenib. It is a tablet, for suspension taken oral. Consult your doctor for specific uses.
Is Tafinlar a controlled substance?
Tafinlar is not classified as a controlled substance by the DEA.
What is the generic name for Tafinlar?
The generic name for Tafinlar is dabrafenib. There are no other listed brand versions of dabrafenib.
What is the NDC code for Tafinlar 10 mg/1?
The NDC (National Drug Code) for Tafinlar 10 mg/1 is 0078-1154, listed by Novartis Pharmaceuticals Corporation.
Other Tafinlar Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)